Atrial Fibrillation
Read Time: 2 mins

119/The long-term effect of thoracoscopic ablation on atrial fibrillation burden using continuous monitoring

Published Online: October 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr119
Authors: R Dulai (Presenting Author) – East Sussex Healthcare NHS Trust, Eastbourne; C Sugihara – Maidstone and Tunbridge Wells NHS Trust, Maidstone; M Lewis – Royal Sussex County Hospital, Brighton; J Hyde – Royal Sussex County Hospital, Brighton; R Veasey – East Sussex Healthcare NHS Trust, Eastbourne; S Furniss – East Sussex Healthcare NHS Trust, Eastbourne; N Sulke – East Sussex Healthcare NHS Trust, Eastbourne
Quick Links:
Article
Article Information
Article:

Introduction: There are limited long-term data using continuous monitoring to assess outcomes of thoracoscopic ablation in patients with paroxysmal atrial fibrillation (AF). This study evaluated the long-term outcomes of thoracoscopic AF ablation in patients with implantable cardiac devices, allowing long-term beat-to-beat monitoring.

Methods: A total of 19 patients with paroxysmal AF (PAF) undergoing thoracoscopic ablation were evaluated. All patients had either an implantable loop recorder or pacemaker inserted, enabling continuous monitoring. AF burden was measured yearly for 3 years post-procedure. Mean and median AF burden at yearly intervals were compared across time intervals using the repeated measures ANOVA test and Friedman test.

Results: The mean age of patients was 60.0 ± 8.0 years and 11 (58%) were male. The mean AF burden at baseline was 12.9% ± 31.8%. This was reduced to 0.426% ± 1.08% at 1 year, 0% ± 0.0% at 2 years and 3.58% ± 15.6% at 3 years (p=0.068) (Figure 1). The median AF burden at baseline was 0.45% (interquartile range [IQR] 0.00%–0.07%), which significantly reduced to 0.00% at 1 year, 2 years and 3 years (IQR 0.00%–0.00%; p=0.01) post-ablation. During the study period, one patient underwent further cavotricuspid isthmus ablation and one patient underwent endocardial atrial tachycardia ablation using 3D electroanatomical mapping.

Conclusion: Thoracoscopic ablation resulted in excellent short-term and long-term arrhythmia outcomes with a significant reduction in median AF burden to 0% and a strong trend to reduction in mean AF burden seen up to 3 years post-ablation. 

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72